Document is current
Any future updates will be listed below
-
Authors
Mastellos, Dimitrios C. http://orcid.org/0000-0002-6634-3271
Hajishengallis, George http://orcid.org/0000-0001-7392-8852
Lambris, John D.
- License Information
-
More Information
Article History
Accepted: 20 July 2023
First Online: 5 September 2023
Competing interests
: J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogues such as AMY-101). J.D.L. is an inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D.L. and G.H. have a joint patent that describes the use of complement inhibitors for therapeutic purposes in periodontitis. J.D.L. is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (namely 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan/Empaveli/Aspaveli/Syfovre). D.C.M. has provided paid consulting services to 4D Molecular Therapeutics and Merck KGaA.
